Nordion to Host Interactive TheraSphere® Educational Session at the SIR Annual Scientific Meeting 2013
Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and
services for the prevention, diagnosis and treatment of disease, will
host an educational session called “TheraSphere®
Test Flight Interactive: How to Treat or Should I Treat?” at
the Society for Interventional Radiologists (SIR) Annual Scientific
Meeting, taking place April 13-18 in New Orleans, Louisiana. The session
is part of SIR’s new Industry Interactive Program, developed to provide
industry partners with the opportunity to host dynamic sessions that
showcase the latest Interventional Radiology technologies and research,
including TheraSphere, Nordion’s Y-90
microsphere treatment for Hepatocellular
Carcinoma (HCC).
“Nordion’s session will feature HCC case presentations delivered by
leading physicians to challenge expert panelists in their thinking,
technique, and opinion on how, or if, they would proceed with
TheraSphere treatment,” said Steve West, Nordion’s Chief Executive
Officer and Chief Operating Officer, Targeted Therapies. “Nordion is
always looking at ways to enhance the TheraSphere learning experience,
and this interactive session is a great complement to our physician
educational portfolio consisting of our Centers of Excellence, proctor
training and preceptor program.”
The TheraSphere® Test Flight Interactive will take place on
Sunday, April 14 from 5:15-6:30 p.m. CDT, in the Ernest N. Morial
Convention Center, Second Floor, Room 271. Scheduled panelists are:
-
Bulent Arslan, Director Interventional Radiology, Rush University;
-
Matthew Johnson, Professor Radiology and Surgery, Indiana University;
and
-
Daniel Sze, Professor, Interventional Radiology, Stanford University.
Cases will be presented by physicians from hospitals across North
America.
“The TheraSphere® Test Flight Interactive session will be a great
forum for experienced TheraSphere users to share expertise and to assist
colleagues in making informed decisions regarding the treatment of
patients in different HCC scenarios,” said Dr. Sze. “Nordion’s
participation in the new Industry Interactive Program demonstrates their
continued commitment to work with SIR and with Interventional
Radiologists to improve care for HCC patients.”
Also at the annual meeting, visit Nordion representatives at Booth #1247
to talk about TheraSphere and:
-
Get a hands-on training opportunity with the TheraSphere
Administration delivery system;
-
Preview the upcoming Treatment Window Illustrator iPad app;
-
Learn more about our Phase III trials and investigator initiated
studies.
About TheraSphere®
TheraSphere is a liver
cancer therapy that consists of millions of small glass beads (20 to
30 micrometers in diameter) containing radioactive
Y-90. The product is injected by physicians into the artery of the
patient’s liver through a catheter, which allows the treatment to be
delivered directly to the tumour via blood flow.
In the US, TheraSphere is used for radiation treatment of patients with
unresectable hepatocellular
carcinoma (HCC) who can have appropriately positioned hepatic
arterial catheters, and can be used as a bridge to surgery or
transplantation in these patients. It is also indicated for the
treatment of HCC patients with partial or branch portal vein thrombosis
or occlusion when clinical evaluation warrants the treatment.
TheraSphere is approved by the U.S. Food and Drug Administration (FDA)
under a Humanitarian Device Exemption (HDE). HDE approvals are based on
demonstrated safety and probable clinical benefit. However,
effectiveness of the indication for use has not been established.
TheraSphere is used in the European Union and in Canada for the
treatment of hepatic neoplasia in patients who have appropriately
positioned arterial catheters.
Common side effects include mild to moderate fatigue, pain and nausea
for about a week. Physicians describe these symptoms as similar to those
of the flu. Some patients experience some loss of appetite and temporary
changes in several blood tests. For details on rare or more severe side
effects, please refer to the TheraSphere package insert/instructions for
use at www.nordion.com/therasphere.
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a
global health science company that provides market-leading products used
for the prevention, diagnosis and treatment of disease. We are a leading
provider of targeted therapies, sterilization technologies, and medical
isotopes that benefit the lives of millions of people in more than 60
countries around the world. Our products are used daily by
pharmaceutical and biotechnology companies, medical-device
manufacturers, hospitals, clinics and research laboratories. Nordion has
approximately 500 highly skilled employees worldwide. Find out more at www.nordion.com
and follow us at http://twitter.com/NordionInc.